1. Home
  2. PCT vs MESO Comparison

PCT vs MESO Comparison

Compare PCT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PureCycle Technologies Inc.

PCT

PureCycle Technologies Inc.

HOLD

Current Price

$11.36

Market Cap

2.3B

Sector

Utilities

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$15.18

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCT
MESO
Founded
2015
2004
Country
United States
Australia
Employees
174
81
Industry
Environmental Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PCT
MESO
Price
$11.36
$15.18
Analyst Decision
Buy
Strong Buy
Analyst Count
3
1
Target Price
$13.00
N/A
AVG Volume (30 Days)
4.7M
138.6K
Earning Date
05-06-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$380.44
$629.74
Revenue Next Year
$203.33
$30.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$9.88
52 Week High
$17.37
$21.50

Technical Indicators

Market Signals
Indicator
PCT
MESO
Relative Strength Index (RSI) 67.12 51.33
Support Level $7.87 $14.19
Resistance Level $15.13 $16.31
Average True Range (ATR) 0.85 0.36
MACD 0.13 -0.01
Stochastic Oscillator 66.58 52.35

Price Performance

Historical Comparison
PCT
MESO

About PCT PureCycle Technologies Inc.

PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: